Drug Trial Radar · NCT05435170
Food Effect Study of Linerixibat Tablets in Healthy Adult Participants
Last checked: Nov 20, 2026Latest source record: Nov 29, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
23
Actual
Start
Aug 11, 2022
Primary completion
Oct 10, 2022
Study completion Oct 10, 2022
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Jun 28, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will evaluate the effect of food on the Pharmacokinetic (PK) and Pharmacodynamic (PD) parameters of linerixibat administered in fed and fasted states in heathy adult participants
Conditions
- Pruritus
Interventions
linerixibatDrug
linerixibat will be administered per the treatment sequence
Primary outcomes
What the sponsor says the trial is designed to measure.
- Plasma linerixibat area under the concentration-time curve from time zero (pre-dose) to the time of the last quantifiable concentration [AUC(0-t)]Time frame: Up to 36 hours post dose
- Maximum observed plasma concentration (Cmax) of linerixibatTime frame: Up to 36 hours post dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Cambridge, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.